Analyst Viewpoint
Rise in prevalence of dry eye syndrome and increase in R&D activities for effective drug development are fueling the dry eye disease market size. Excessive screen time and increase in usage of cosmetic lenses are causing dry eye syndrome. Growth in geriatric population and rise in popularity of digital education systems are augmenting market expansion.
Leading companies in the market are focusing on research to develop effective chronic dry eye disease treatment options and diagnostic tools. Furthermore, innovation in drug development and rise in number of clinical trials are likely to offer lucrative dry eye disease market opportunities to pharmaceutical companies. They are investing significantly to introduce new drugs to deal with dry eye syndrome.
Dry eye disease, also called Keratoconjunctivitis Sicca (KCS), is a common ophthalmic condition that occurs when a person does not have adequate tears for lubricating or nourishing the eye. Redness, scratching, stinging, watery eyes, light sensitivity, burning sensation, stringy mucus near the eyes, and blurred vision are some of the evident symptoms of dry eye disease. Evaporative dry eye disease and aqueous deficiency dry eye disease are two common types of dry eye disease.
Tear film dysfunction, or dry eye disease, can be caused by several reasons, such as allergic reactions, autoimmune diseases, hormone changes, or inflamed eyelid glands. Dry eye disease can be elevated by various factors, including refractive surgeries, aging, pollution, excessive screen time, use of contact lenses for prolonged periods, and diabetes. Physicians rely on artificial tears to treat dry eye diseases at the initial stage.
The geriatric population is more susceptible to dry eye syndrome, as the ability of lacrimal glands to produce decreases with age. Thus, the geriatric population can have ophthalmic ailments, such as blurred vision, redness, dryness, and eye discomfort. Moreover, various diseases, including diabetes, thyroid disease, Sjogren's syndrome, scab, scleroderma, and rheumatoid arthritis also contribute to the spread of dry eye in the elderly population. Hence, increase in prevalence of dry eye syndrome is augmenting the dry eye disease market value.
Increase in screen time over laptops, computers, televisions, and smartphones is propelling the dry eye disease market growth. Spending too much time on screens can create strain the eyes, as people tend to blink less while staring at a screen. According to the National Institutes of Health, screen time is a major concern causing digital eye strain. The most commonly reported symptoms were eye fatigue (53.3%), blurred vision (38.9%), and irritated or burning eyes (34.2%). Thus, high screen time among adults and kids is fostering market progress.
Pharmaceutical companies are heavily investing in introducing effective treatments for dry eye disease. Healthcare professionals focus on analyzing the symptoms for early detection of the syndrome. Increase in research and development activities to understand the cause of the diseases and accordingly provide age-appropriate treatment is boosting the dry eye disease market revenue. Hence, easy accessibility and availability of medical facilities is driving the market value.
Increase in popularity of cosmetic lenses in the beauty sector is causing tear film dysfunction, thereby fostering the growth of the dry eye disease industry. Regular use of cosmetic lenses can lead to eye issues, such as infections, redness, blurred vision, and corneal ulcers. It can further lead to severe issues, such as swelling and even vision loss.
As per the dry eye disease market analysis, North America held a dominant position in the global market in 2022. Growth in adoption of prescription drugs and increase in R&D in drug development are driving market statistics. Moreover, availability of medical facilities and government approvals for new drugs are projected to propel the dry eye disease industry share in the near future.
Excessive screen time and increase in use of smartphones among children are likely to increase the prevalence of several eye diseases. For instance, according to the Centers for Disease Control and Prevention, approximately 6.8% of children younger than 18 years in the U.S. have a diagnosed eye and vision condition. Nearly 3.0% of children younger than 18 years are blind or visually impaired.
Leading pharmaceutical companies are focusing on drug development by conducting future analysis of dry eye disease and its symptoms. They are investing in innovative drug development and conducting clinical trials to get approvals. Leading players in the market are adopting various strategies such as mergers and acquisitions, business agreements, and partnerships to expand their production capacities.
Some of the leading companies in the industry are Santen Pharmaceutical Co., Ltd., Novartis AG, Bausch Health Companies Inc., Allergan plc, Shire plc, TRB Chemedica International SA, Sun Pharmaceutical Industries Ltd., Senju Pharmaceutical Co., Ltd., Sentiss Pharma Pvt. Ltd., Johnson & Johnson, Otsuka Pharmaceutical Co., Ltd., Mitotech S.A., and FCI.
Key players in the dry eye disease market report have been profiled based on various parameters such as company overview, financial overview, business segments, product portfolio, business strategies, and key developments.
| Attribute | Detail |
|---|---|
| Market Size in 2022 | US$ 6.1 Bn |
| Market Forecast (Value) in 2031 | US$ 8.7 Bn |
| Growth Rate (CAGR) | 4.2% |
| Forecast Period | 2023-2031 |
| Historical Data Available for | 2017-2021 |
| Quantitative Tons | US$ Bn for Value: |
| Market Analysis | It includes segment analysis as well as regional level analysis. Furthermore, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces Analysis, value chain analysis, and key trend analysis. |
| Competition Landscape |
|
| Format | Electronic (PDF) + Excel |
| Market Segmentation |
|
| Regions Covered |
|
| Countries Covered |
|
| Companies Profiled |
|
| Customization Scope | Available upon request |
| Pricing | Available upon request |
The global market was valued at US$ 6.1 Bn in 2022
It is projected to expand at a CAGR of 4.2% from 2023 to 2031
Rise in prevalence of dry eye syndrome and increase in R&D activities for effective drug development
North America was the most lucrative region in 2022
Santen Pharmaceutical Co., Ltd., Novartis AG, Bausch Health Companies Inc., Allergan plc, Shire plc, TRB Chemedica International SA, Sun Pharmaceutical Industries Ltd., Senju Pharmaceutical Co., Ltd., Sentiss Pharma Pvt. Ltd., Johnson & Johnson, Otsuka Pharmaceutical Co., Ltd., Mitotech S.A., and FCI.
1. Executive Summary
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Dry Eye Disease Market
4. Market Overview
4.1. Market Segmentation
4.1.1. Segment Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Dry Eye Disease Market Analysis and Forecast, 2017-2031
5. Key Insights
5.1. Pipeline Analysis
5.2. Disease Prevalence & Incidence Rate Globally With Key Countries
5.3. COVID-19 Pandemic Impact on Industry
6. Dry Eye Disease Market Analysis and Forecast, by Product
6.1. Introduction and Definitions
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Product, 2017–2031
6.3.1. Artificial Tears
6.3.2. Anti-inflammatory Drugs
6.3.3. Cyclosporine
6.3.4. Corticosteroids
6.3.5. Lifitegrast
6.3.6. Punctual Plugs
6.3.7. Secretagogue
6.3.8. Others
6.4. Market Attractiveness, by Product
7. Global Dry Eye Disease Market Analysis and Forecast, by Distribution Channel
7.1. Introduction and Definitions
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Distribution Channel, 2017–2031
7.3.1. Hospital Pharmacies
7.3.2. Independent Pharmacies & Drug Stores
7.3.3. Online Pharmacies
7.4. Market Attractiveness, by Distribution Channel
8. Global Dry Eye Disease Market Analysis and Forecast, by Region
8.1. Key Findings
8.2. Market Value Forecast, by Region, 2017–2031
8.2.1. North America
8.2.2. Europe
8.2.3. Asia Pacific
8.2.4. Latin America
8.2.5. Middle East & Africa
8.3. Market Attractiveness, by Region
9. North America Dry Eye Disease Market Analysis and Forecast
9.1. Introduction
9.1.1. Key Findings
9.2. Market Value Forecast, by Product, 2017–2031
9.2.1. Artificial Tears
9.2.2. Anti-inflammatory Drugs
9.2.3. Cyclosporine
9.2.4. Corticosteroids
9.2.5. Lifitegrast
9.2.6. Punctual Plugs
9.2.7. Secretagogue
9.2.8. Others
9.3. Market Value Forecast, by Distribution Channel, 2017–2031
9.3.1. Hospital Pharmacies
9.3.2. Independent Pharmacies & Drug Stores
9.3.3. Online Pharmacies
9.4. Market Value Forecast, by Country, 2017–2031
9.4.1. U.S.
9.4.2. Canada
9.5. Market Attractiveness Analysis
9.5.1. By Product
9.5.2. By Distribution Channel
9.5.3. By Country
10. Europe Dry Eye Disease Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Product, 2017–2031
10.2.1. Artificial Tears
10.2.2. Anti-inflammatory Drugs
10.2.3. Cyclosporine
10.2.4. Corticosteroids
10.2.5. Lifitegrast
10.2.6. Punctual Plugs
10.2.7. Secretagogue
10.2.8. Others
10.3. Market Value Forecast, by Distribution Channel, 2017–2031
10.3.1. Hospital Pharmacies
10.3.2. Independent Pharmacies & Drug Stores
10.3.3. Online Pharmacies
10.4. Market Value Forecast, by Country/Sub-region, 2017–2031
10.4.1. Germany
10.4.2. U.K.
10.4.3. France
10.4.4. Italy
10.4.5. Spain
10.4.6. Rest of Europe
10.5. Market Attractiveness Analysis
10.5.1. By Product
10.5.2. By Distribution Channel
10.5.3. By Country/Sub-region
11. Asia Pacific Dry Eye Disease Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Product, 2017–2031
11.2.1. Artificial Tears
11.2.2. Anti-inflammatory Drugs
11.2.3. Cyclosporine
11.2.4. Corticosteroids
11.2.5. Lifitegrast
11.2.6. Punctual Plugs
11.2.7. Secretagogue
11.2.8. Others
11.3. Market Value Forecast, by Distribution Channel, 2017–2031
11.3.1. Hospital Pharmacies
11.3.2. Independent Pharmacies & Drug Stores
11.3.3. Online Pharmacies
11.4. Market Value Forecast, by Country/Sub-region, 2017–2031
11.4.1. China
11.4.2. Japan
11.4.3. India
11.4.4. Australia & New Zealand
11.4.5. Rest of Asia Pacific
11.5. Market Attractiveness Analysis
11.5.1. By Product
11.5.2. By Distribution Channel
11.5.3. By Country/Sub-region
12. Latin America Dry Eye Disease Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Product, 2017–2031
12.2.1. Artificial Tears
12.2.2. Anti-inflammatory Drugs
12.2.3. Cyclosporine
12.2.4. Corticosteroids
12.2.5. Lifitegrast
12.2.6. Punctual Plugs
12.2.7. Secretagogue
12.2.8. Others
12.3. Market Value Forecast, by Distribution Channel, 2017–2031
12.3.1. Hospital Pharmacies
12.3.2. Independent Pharmacies & Drug Stores
12.3.3. Online Pharmacies
12.4. Market Value Forecast, by Country/Sub-region, 2017–2031
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Rest of Latin America
12.5. Market Attractiveness Analysis
12.5.1. By Product
12.5.2. By Distribution Channel
12.5.3. By Country/Sub-region
13. Middle East & Africa Dry Eye Disease Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Product, 2017–2031
13.2.1. Artificial Tears
13.2.2. Anti-inflammatory Drugs
13.2.3. Cyclosporine
13.2.4. Corticosteroids
13.2.5. Lifitegrast
13.2.6. Punctual Plugs
13.2.7. Secretagogue
13.2.8. Others
13.3. Market Value Forecast, by Distribution Channel, 2017–2031
13.3.1. Hospital Pharmacies
13.3.2. Independent Pharmacies & Drug Stores
13.3.3. Online Pharmacies
13.4. Market Value Forecast, by Country/Sub-region, 2017–2031
13.4.1. GCC Countries
13.4.2. South Africa
13.4.3. Rest of Middle East & Africa
13.5. Market Attractiveness Analysis
13.5.1. By Product
13.5.2. By Distribution Channel
13.5.3. By Country/Sub-region
14. Competition Landscape
14.1. Market Player - Competition Matrix (By Tier and Size of Companies)
14.2. Market Share Analysis, by Company (2022)
14.3. Company Profiles
14.3.1. Santen Pharmaceutical Co., Ltd.
14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.1.2. Product Portfolio
14.3.1.3. Financial Overview
14.3.1.4. SWOT Analysis
14.3.1.5. Strategic Overview
14.3.2. Novartis AG
14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.2.2. Product Portfolio
14.3.2.3. Financial Overview
14.3.2.4. SWOT Analysis
14.3.2.5. Strategic Overview
14.3.3. Bausch Health Companies Inc.
14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.3.2. Product Portfolio
14.3.3.3. Financial Overview
14.3.3.4. SWOT Analysis
14.3.3.5. Strategic Overview
14.3.4. Allergan plc
14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.4.2. Product Portfolio
14.3.4.3. Financial Overview
14.3.4.4. SWOT Analysis
14.3.4.5. Strategic Overview
14.3.5. Shire plc
14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.5.2. Product Portfolio
14.3.5.3. Financial Overview
14.3.5.4. SWOT Analysis
14.3.5.5. Strategic Overview
14.3.6. TRB Chemedica International SA
14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.6.2. Product Portfolio
14.3.6.3. Financial Overview
14.3.6.4. SWOT Analysis
14.3.6.5. Strategic Overview
14.3.7. Sun Pharmaceutical Industries Ltd.
14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.7.2. Product Portfolio
14.3.7.3. Financial Overview
14.3.7.4. SWOT Analysis
14.3.7.5. Strategic Overview
14.3.8. Senju Pharmaceutical Co., Ltd.
14.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.8.2. Product Portfolio
14.3.8.3. Financial Overview
14.3.8.4. SWOT Analysis
14.3.8.5. Strategic Overview
14.3.9. Sentiss Pharma Pvt. Ltd.
14.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.9.2. Product Portfolio
14.3.9.3. Financial Overview
14.3.9.4. SWOT Analysis
14.3.9.5. Strategic Overview
14.3.10. Johnson & Johnson
14.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.10.2. Product Portfolio
14.3.10.3. Financial Overview
14.3.10.4. SWOT Analysis
14.3.10.5. Strategic Overview
14.3.11. Otsuka Pharmaceutical Co., Ltd.
14.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.11.2. Product Portfolio
14.3.11.3. Financial Overview
14.3.11.4. SWOT Analysis
14.3.11.5. Strategic Overview
14.3.12. Mitotech S.A.
14.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.12.2. Product Portfolio
14.3.12.3. Financial Overview
14.3.12.4. SWOT Analysis
14.3.12.5. Strategic Overview
14.3.13. FCI
14.3.13.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.13.2. Product Portfolio
14.3.13.3. Financial Overview
14.3.13.4. SWOT Analysis
14.3.13.5. Strategic Overview
List of Tables
Table 01: Global Dry Eye Disease Market Value (US$ Mn) Forecast, by Application, 2017–2031
Table 02: Global Dry Eye Disease Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 03: Global Dry Eye Disease Market Value (US$ Mn) Forecast, by Region, 2017–2031
Table 04: North America Dry Eye Disease Market Value (US$ Mn) Forecast, by Application, 2017–2031
Table 05: North America Dry Eye Disease Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 06: North America Dry Eye Disease Market Value (US$ Mn) Forecast, by Country, 2017–2031
Table 07: Europe Dry Eye Disease Market Value (US$ Mn) Forecast, by Application, 2017–2031
Table 08: Europe Dry Eye Disease Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 09: Europe Dry Eye Disease Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 10: Asia Pacific Dry Eye Disease Market Value (US$ Mn) Forecast, by Application, 2017–2031
Table 11: Asia Pacific Dry Eye Disease Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 12: Asia Pacific Dry Eye Disease Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 13: Latin America Dry Eye Disease Market Value (US$ Mn) Forecast, by Application, 2017–2031
Table 14: Latin America Dry Eye Disease Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 15: Latin America Dry Eye Disease Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 16: Middle East & Africa Dry Eye Disease Market Value (US$ Mn) Forecast, by Application, 2017–2031
Table 17: Middle East & Africa Dry Eye Disease Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 18: Middle East & Africa Dry Eye Disease Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
List of Figures
Figure 01: Global Dry Eye Disease Market Value (US$ Mn) Forecast, 2017–2031
Figure 02: Global Dry Eye Disease Market Value Share Analysis, by Application 2022 and 2031
Figure 03: Global Dry Eye Disease Market Attractiveness Analysis, by Application, 2023–2031
Figure 04: Global Dry Eye Disease Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 05: Global Dry Eye Disease Market Attractiveness Analysis, by Distribution Channel, 2023–2031
Figure 06: Global Dry Eye Disease Market Value Share Analysis, by Region, 2022 and 2031
Figure 07: Global Dry Eye Disease Market Attractiveness Analysis, by Region, 2023–2031
Figure 08: North America Dry Eye Disease Market Value (US$ Mn) Forecast, 2017–2031
Figure 09: North America Dry Eye Disease Market Value Share Analysis, by Application, 2022 and 2031
Figure 10: North America Dry Eye Disease Market Attractiveness Analysis, by Application, 2023–2031
Figure 11: North America Dry Eye Disease Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 12: North America Dry Eye Disease Market Attractiveness Analysis, by Distribution Channel, 2023–2031
Figure 13: North America Dry Eye Disease Market Value Share Analysis, by Country, 2022 and 2031
Figure 14: North America Dry Eye Disease Market Attractiveness Analysis, by Country, 2023–2031
Figure 15: Europe Dry Eye Disease Market Value (US$ Mn) Forecast, 2017–2031
Figure 16: Europe Dry Eye Disease Market Value Share Analysis, by Application, 2022 and 2031
Figure 17: Europe Dry Eye Disease Market Attractiveness Analysis, by Application, 2023–2031
Figure 18: Europe Dry Eye Disease Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 19: Europe Dry Eye Disease Market Attractiveness Analysis, by Distribution Channel, 2023–2031
Figure 20: Europe Dry Eye Disease Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 21: Europe Dry Eye Disease Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 22: Asia Pacific Dry Eye Disease Market Value (US$ Mn) Forecast, 2017–2031
Figure 23: Asia Pacific Dry Eye Disease Market Value Share Analysis, by Application 2022 and 2031
Figure 24: Asia Pacific Dry Eye Disease Market Attractiveness Analysis, by Application, 2023–2031
Figure 25: Asia Pacific Dry Eye Disease Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 26: Asia Pacific Dry Eye Disease Market Attractiveness Analysis, by Distribution Channel, 2023–2031
Figure 27: Asia Pacific Dry Eye Disease Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 28: Asia Pacific Dry Eye Disease Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 29: Latin America Dry Eye Disease Market Value (US$ Mn) Forecast, 2017–2031
Figure 30: Latin America Dry Eye Disease Market Value Share Analysis, by Application, 2022 and 2031
Figure 31: Latin America Dry Eye Disease Market Attractiveness Analysis, by Application, 2023–2031
Figure 32: Latin America Dry Eye Disease Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 33: Latin America Dry Eye Disease Market Attractiveness Analysis, by Distribution Channel, 2023–2031
Figure 34: Latin America Dry Eye Disease Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 35: Latin America Dry Eye Disease Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 36: Middle East & Africa Dry Eye Disease Market Value (US$ Mn) Forecast, 2017–2031
Figure 37: Middle East & Africa Dry Eye Disease Market Value Share Analysis, by Application, 2022 and 2031
Figure 38: Middle East & Africa Dry Eye Disease Market Attractiveness Analysis, by Application, 2023–2031
Figure 39: Middle East & Africa Dry Eye Disease Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 40: Middle East & Africa Dry Eye Disease Market Attractiveness Analysis, by Distribution Channel, 2023–2031
Figure 41: Middle East & Africa Dry Eye Disease Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 42: Middle East & Africa Dry Eye Disease Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 43: Global Dry Eye Disease Market Share Analysis, by Company, 2022
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Dry Eye Disease Market
